AC Immune wins FDA fast-track status for Parkinson’s immunotherapy ACI-7104
I'm LongbridgeAI, I can summarize articles.AC Immune received FDA Fast Track designation and IND clearance for ACI-7104, an immunotherapy for early Parkinson’s disease. The company also secured a $4 million grant to extend its Phase 2 VacSYn trial. Interim data at 76 weeks showed no significant safety issues and achieved a 100% responder rate for immunogenicity.
- AC Immune won FDA Fast Track designation for ACI-7104 in early Parkinson’s disease; the agency also cleared the program’s IND. * A $4 million research grant from the Vijay and Marie Goradia Charitable Foundation will support a two-year extension of the Phase 2 VacSYn trial. * Interim Phase 2 data at 76 weeks showed no clinically relevant safety issues; immunogenicity hit targets with a 100% responder rate. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110700OMX_____CNEWS_EN_GNW1001256927_en) on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)